Literature DB >> 21697181

Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides.

Wei Ying Yue1, J Jason Clark, Augusta Fernando, Frederick Domann, Marlan R Hansen.   

Abstract

Vestibular schwannomas (VSs) result from inactivating mutations in the merlin tumor suppressor gene. The merlin protein suppresses a variety of progrowth kinase-signaling cascades, including extracellular regulated kinase/mitogen-activated protein kinase (ERK/MAPK), c-Jun N-terminal kinase (JNK), and phosphatidyl-inositol 3-kinase (PI3-K)/Akt. Recent studies indicate that ERKs and Akt are active in human VSs, and here we show that JNKs are also persistently active in human VS cells. With use of cultures of human VSs, we investigated the contribution of each of these signals to the proliferative and survival response of VS cells. Inhibition of ERK or Akt signaling reduced VS cell proliferation but did not increase apoptosis, whereas inhibition of JNK with SP600125, I-JIP, or siRNA knock-down reduced VS cell proliferation and survival by inducing apoptosis. By contrast, JNK activity promotes apoptosis in normal Schwann cells. Inhibition of JNK increased the fluorescence intensity of VS cells loaded with 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate (H(2)DCFDA), a fluorescent probe for reactive oxygen species (ROS). Furthermore, ebselen, a ROS scavenger, rescued VS cells with suppressed JNK from apoptosis, suggesting that JNK activity protects VS cells from apoptosis by limiting accumulation of ROS. VS cultures treated with JNK inhibitors demonstrated significantly higher levels of MitoSOX Red fluorescence, implying that persistent JNK activity specifically suppresses superoxide production in the mitochondria. Overexpression of superoxide dismutase 2 (MnSOD; mitochondrial SOD) prevented apoptosis in VS cells with suppressed JNK signaling. Taken together, these results indicate that persistent JNK activity enhances VS cell survival, at least in part, by suppressing accumulation of mitochondrial superoxides.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21697181      PMCID: PMC3158009          DOI: 10.1093/neuonc/nor068

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  48 in total

Review 1.  The biochemistry of apoptosis.

Authors:  M O Hengartner
Journal:  Nature       Date:  2000-10-12       Impact factor: 49.962

2.  Insulin-like growth factor-I and Bcl-X(L) inhibit c-jun N-terminal kinase activation and rescue Schwann cells from apoptosis.

Authors:  H L Cheng; M L Steinway; X Xin; E L Feldman
Journal:  J Neurochem       Date:  2001-02       Impact factor: 5.372

3.  Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway.

Authors:  C Tournier; P Hess; D D Yang; J Xu; T K Turner; A Nimnual; D Bar-Sagi; S N Jones; R A Flavell; R J Davis
Journal:  Science       Date:  2000-05-05       Impact factor: 47.728

4.  Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.

Authors:  Wei Li; Liru You; Jonathan Cooper; Gaia Schiavon; Angela Pepe-Caprio; Lu Zhou; Ryohei Ishii; Marco Giovannini; C Oliver Hanemann; Stephen B Long; Hediye Erdjument-Bromage; Pengbo Zhou; Paul Tempst; Filippo G Giancotti
Journal:  Cell       Date:  2010-02-19       Impact factor: 41.582

5.  MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival.

Authors:  Joseph A Cioffi; Wei Ying Yue; Sabrina Mendolia-Loffredo; Kameron R Hansen; P Ashley Wackym; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2010-12       Impact factor: 2.311

6.  Transforming growth factor beta (TGFbeta) mediates Schwann cell death in vitro and in vivo: examination of c-Jun activation, interactions with survival signals, and the relationship of TGFbeta-mediated death to Schwann cell differentiation.

Authors:  D B Parkinson; Z Dong; H Bunting; J Whitfield; C Meier; H Marie; R Mirsky; K R Jessen
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

7.  Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.

Authors:  Tina X Lee; Mark D Packer; Jie Huang; Elena M Akhmametyeva; Samuel K Kulp; Ching-Shih Chen; Marco Giovannini; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Eur J Cancer       Date:  2009-04-07       Impact factor: 9.162

8.  NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

Authors:  Marianne F James; Sangyeul Han; Carolyn Polizzano; Scott R Plotkin; Brendan D Manning; Anat O Stemmer-Rachamimov; James F Gusella; Vijaya Ramesh
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

9.  The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner.

Authors:  S Sean Houshmandi; Ryan J Emnett; Marco Giovannini; David H Gutmann
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

10.  Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ.

Authors:  David A Hilton; Natalia Ristic; Clemens O Hanemann
Journal:  Histopathology       Date:  2009-12       Impact factor: 5.087

View more
  11 in total

1.  Merlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury.

Authors:  Iram Ahmad; Augusta Fernando; Richard Gurgel; J Jason Clark; Linjing Xu; Marlan R Hansen
Journal:  Neurobiol Dis       Date:  2015-06-06       Impact factor: 5.996

2.  Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.

Authors:  Jennifer Kersigo; Lintao Gu; Linjing Xu; Ning Pan; Sarath Vijayakuma; Timothy Jones; Seiji B Shibata; Bernd Fritzsch; Marlan R Hansen
Journal:  Laryngoscope       Date:  2020-05-21       Impact factor: 3.325

3.  Ebselen alters mitochondrial physiology and reduces viability of rat hippocampal astrocytes.

Authors:  Patricia Santofimia-Castaño; Ginés M Salido; Antonio González
Journal:  DNA Cell Biol       Date:  2013-03-15       Impact factor: 3.311

4.  Inhibition of c-Jun N-terminal kinase activity enhances vestibular schwannoma cell sensitivity to gamma irradiation.

Authors:  Wei Ying Yue; J Jason Clark; Michael Telisak; Marlan R Hansen
Journal:  Neurosurgery       Date:  2013-09       Impact factor: 4.654

5.  p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.

Authors:  Iram Ahmad; Wei Ying Yue; Augusta Fernando; J Jason Clark; Erika A Woodson; Marlan R Hansen
Journal:  Glia       Date:  2014-06-26       Impact factor: 7.452

6.  Persistent Oxidative Stress in Vestibular Schwannomas After Stereotactic Radiation Therapy.

Authors:  Zachary N Robinett; Girish Bathla; Angela Wu; James Jason Clark; Zita A Sibenaller; Thomas Wilson; Patricia Kirby; Bryan G Allen; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2018-10       Impact factor: 2.311

7.  JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells.

Authors:  Shuhei Suzuki; Masashi Okada; Keita Shibuya; Manabu Seino; Atsushi Sato; Hiroyuki Takeda; Shizuka Seino; Takashi Yoshioka; Chifumi Kitanaka
Journal:  Oncotarget       Date:  2015-01-01

8.  Schwannomas provide insight into the role of p75(NTR) and merlin in Schwann cells following nerve injury and during regeneration.

Authors:  Elise Cheng; Marlan R Hansen
Journal:  Neural Regen Res       Date:  2016-01       Impact factor: 5.135

Review 9.  The biological underpinnings of radiation therapy for vestibular schwannomas: Review of the literature.

Authors:  Mark C Dougherty; Seiji B Shibata; Marlan R Hansen
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-03-30

10.  Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells.

Authors:  Yixuan Sun; Xinlu Yuan; Feifei Zhang; Yamei Han; Xinxia Chang; Xi Xu; Yu Li; Xin Gao
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.